# US 2023/0398226 A1 · Compositions and methods for the treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398226 A1
- Document ID: US20230398226A1
- Status: Published application
- Kind: A1
- Application number: 17/887,776
- Filed: 2022-08-15
- Published: 2023-12-14
- Earliest claimed: 2019-09-06
- Assignees: Cidara Therapeutics, Inc.
- Applicants: Cidara Therapeutics, Inc.
- Inventors: Allen BORCHARDT; Thomas P. BRADY; Zhi-Yong CHEN; Thanh LAM; Leslie W. TARI
- Web page: https://patentgrep.com/patent/US20230398226A1

## CPC

- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61P 31/16: for influenza or rhinoviruses
- C07D 309/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

## Claims

### Claim 1

A method of treating a subject having an influenza infection, the method comprising administering to the subject a conjugate described by formula (D-II-6):
wherein each E comprises an Fc domain monomer;
n is 1 or 2;
T is an integer from 1 to 20;
L is a linker;
R7 is selected from C1-C20 alkyl; and
the squiggly line indicates that L is covalently attached to E;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the squiggly line indicates that L is covalently attached to a nitrogen atom of a solvent-exposed lysine of E.

### Claim 3 (depends on 1)

The method of claim 1, wherein the squiggly line indicates that L is covalently attached to a sulfur atom of a solvent-exposed cysteine of E.

### Claim 4 (depends on 1)

The method of claim 1, wherein n is 2, and the two Es dimerize with each other to form an Fc domain.

### Claim 5 (depends on 1)

The method of claim 1, wherein T is an integer from 1 to 10.

### Claim 6 (depends on 1)

The method of claim 1, wherein R7 is methyl, ethyl, propyl, or butyl.

### Claim 7 (depends on 6)

The method of claim 6, wherein the conjugate is described by formula (D-II-7):
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the conjugate is described by formula (D-II-8):
wherein L′ is the remainder of L, and
y1 and y2 are each independently an integer from 1-20,
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein n is 2, and the two Es dimerize with each other to form an Fc domain.

### Claim 12 (depends on 1)

The method of claim 1, wherein each E comprises an amino acid sequence independently selected from of any one of SEQ ID NOs: 1-138.

### Claim 13 (depends on 1)

The method of claim 1, wherein each E comprises an amino acid sequence independently selected from any one of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 76, and SEQ ID NO: 77.

### Claim 14 (depends on 1)

The method of claim 1, wherein the influenza virus is influenza virus A, influenza virus B, influenza virus C, or a parainfluenza virus.

### Claim 15

A method of treating a subject having an influenza infection, the method comprising administering to the subject a conjugate described by the structure:
wherein J is an Fc domain comprising two Fc domain monomers;
T is an integer from 1 to 20,
L is a linker;
R7 is selected from C1-C20 alkyl; and
the squiggly line indicates that L is covalently attached to J;
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein R7 is methyl, ethyl, propyl, or butyl.

### Claim 17 (depends on 16)

The method of claim 16, wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 15)

The method of claim 15, wherein each Fc domain monomer comprises an amino acid sequence independently selected from any one of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 76, and SEQ ID NO: 77.

### Claim 20 (depends on 15)

The method of claim 15, wherein the influenza virus is influenza virus A, influenza virus B, influenza virus C, or a parainfluenza virus.
